title: [Ultiva (remifentanil hydrochloride), intravenous dose of 2mg, 5mg: pharmacological and clinical profile].
authors.forename: Shunji
authors.initials: S
authors.lastname: Nomura
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Arai
authors.forename: Satoshi
authors.initials: S
authors.lastname: Takeuchi
authors.forename: Akinori
authors.initials: A
authors.lastname: Masui
authors.forename: Akihide
authors.initials: A
authors.lastname: Wakamatsu
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Harada
mesh_terms: D000701:Analgesics, Opioid / Q000008:administration & dosage* / Q000494:pharmacology*; D000768:Anesthesia, General; D018685:Anesthetics, Inhalation; D018686:Anesthetics, Intravenous / Q000008:administration & dosage* / Q000494:pharmacology*; D000818:Animals; D017326:Clinical Trials, Phase III as Topic; D004338:Drug Combinations; D006801:Humans; D007262:Infusions, Intravenous; D008738:Methyl Ethers; D010880:Piperidines / Q000008:administration & dosage* / Q000494:pharmacology*; D015742:Propofol; D017450:Receptors, Opioid, mu / Q000819:agonists / Q000378:metabolism; D000077208:Remifentanil; D000077149:Sevoflurane
chemical_list: D000701:Analgesics, Opioid; D018685:Anesthetics, Inhalation; D018686:Anesthetics, Intravenous; D004338:Drug Combinations; D008738:Methyl Ethers; D010880:Piperidines; D017450:Receptors, Opioid, mu; D000077149:Sevoflurane; D000077208:Remifentanil; D015742:Propofol